Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)

V. Rosengren, E. Ekstrom,L. Forsberg, S. Kagstrom,J. Hillert, P. Nilsson,C. Dahle, A. Svenningsson, J. Lycke, A. -M. Landtblom,J. Burman,C. Martin, P. Sundstrom,M. Gunnarsson,F. Piehl,T. Olsson

MULTIPLE SCLEROSIS JOURNAL(2021)

引用 0|浏览9
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要